Antigonadotropins: A Novel Strategy to Halt Alzheimer's Disease Progression

Authors: Gregory, Christopher W.¹; Atwood, Craig S.¹; Smith, Mark A.¹; Bowen, Richard L.¹

Source: Current Pharmaceutical Design, Volume 12, Number 6, February 2006 , pp. 685-690(6)

Publisher: Bentham Science Publishers

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

More like this?

In this: publication
By this: publisher
In this Subject: Pharmacology
By this author: Gregory, Christopher W. ; Atwood, Craig S. ; Smith, Mark A. ; Bowen, Richard L.

Content Key:

- Free

- New

- Open Access

- Subscribed

- Free Trial

Abstract:

A significant amount of research has been focused on the relationship between hormones and Alzheimer's disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimer's disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimer's disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimer's disease, and discusses potential therapeutic anti-gonadotropin compounds.

Keywords: Luteinizing hormone (LH); follicle-stimulating hormone (FSH); Alzheimer's disease; gonadotropin releasing hormone (GnRH); cell cycle; estrogen

Document Type: Research article

DOI: 10.2174/138161206775474288

Affiliations: 1: Voyager Pharmaceutical Corporation, 8540 Colonnade Center Drive, Suite 501, Raleigh, NC 27615.